Abstract
Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients. However there are concerns regarding its long term tolerance, particularly myelosuppression and malignancy. Azathioprine is not required in about one third of Crohn's Disease patients and more than half of Ulcerative Colitis patients who will experience a mild disease course. In patients with more severe disease, although anti-TNF agents are more powerful and act more rapidly, there is a subset of patients with moderate-to-severe IBD without important anatomical damage who may achieve a prolonged steroid-free clinical and anatomical remission on azathioprine monotherapy. It is thus advised to initiate azathioprine monotherapy in these intermediate cases, and to continue azathioprine if anatomical remission is achieved.
Keywords: Anti-TNF agents, azathioprine, Crohn's disease, mercaptopurine, ulcerative coilitis.
Current Drug Targets
Title:Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?
Volume: 14 Issue: 12
Author(s): Anne Bourrier, Philippe Seksik and Jacques Cosnes
Affiliation:
Keywords: Anti-TNF agents, azathioprine, Crohn's disease, mercaptopurine, ulcerative coilitis.
Abstract: Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients. However there are concerns regarding its long term tolerance, particularly myelosuppression and malignancy. Azathioprine is not required in about one third of Crohn's Disease patients and more than half of Ulcerative Colitis patients who will experience a mild disease course. In patients with more severe disease, although anti-TNF agents are more powerful and act more rapidly, there is a subset of patients with moderate-to-severe IBD without important anatomical damage who may achieve a prolonged steroid-free clinical and anatomical remission on azathioprine monotherapy. It is thus advised to initiate azathioprine monotherapy in these intermediate cases, and to continue azathioprine if anatomical remission is achieved.
Export Options
About this article
Cite this article as:
Bourrier Anne, Seksik Philippe and Cosnes Jacques, Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990172
DOI https://dx.doi.org/10.2174/13894501113149990172 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism The Retrotransposition of L1 is Involved in the Reconsolidation of Contextual Fear Memory in Mice
CNS & Neurological Disorders - Drug Targets Signal Transduction in Human Cutaneous Melanoma and Target Drugs
Current Cancer Drug Targets Topical Chemoprevention of Skin Cancers with Phytochemicals
Current Cancer Therapy Reviews Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry Phospholipid Nanosomes
Current Drug Delivery Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Vitiligo: An Updated Narrative Review
Current Pediatric Reviews The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Current Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design